SPI-1005 for the Treatment of Meniere's Disease (Open Label)

Who can take part

• Adult males/females, 18-75 years of age at the time of enrollment
• Diagnosis of probable or definite Meniere's Disease by AAO-HNS Amended 2015 Criteria
• At least two of three active symptoms (fluctuating hearing; tinnitus; aural fullness; vertigo or dizziness) of Meniere's disease, within 3 months of study enrollment
• Type A tympanogram at screening
• Air conduction thresholds ≤ 90 dB at all tested frequencies (250-8000 Hz) in both ears
• Subject is willing and able to provide informed consent and perform study procedures and assessments per protocol
• Reproductive requirements

Who cannot take part

• Current, or within 60 days prior to study enrollment, use of IV or intratympanic ototoxic medications such as chemotherapy including cisplatin, carboplatin, or oxaliplatin; aminoglycoside antibiotics including gentamicin, amikacin, tobramycin, kanamycin, or streptomycin; or loop diuretics including furosemide
• Current use or within 30 days prior to study enrollment systemic steroids
• Current use or within 7 days prior to study enrollment intratympanic steroids
• Participation in another investigational drug or device study within 30 days prior to study consent
• History of otosclerosis or vestibular schwannoma
• History of significant middle ear or inner ear surgery in the affected ear
• Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, neurological, or psychiatric disease
• Hypersensitivity or idiosyncratic reaction to compounds related to ebselen or excipients
• Conductive hearing loss with air-bone gap ≥15 dB, otitis media, or mixed hearing loss
• Female patients who are pregnant or breastfeeding
• Participant resides more than 100 miles from the study site